Hikma Pharmaceuticals Valuation
| HKMPY Stock | USD 49.81 0.70 1.39% |
At this time, the firm appears to be fairly valued. Hikma Pharmaceuticals PLC retains a regular Real Value of $49.71 per share. The prevalent price of the firm is $49.81. Our model calculates the value of Hikma Pharmaceuticals PLC from evaluating the firm fundamentals such as Return On Equity of 0.15, return on asset of 0.077, and Current Valuation of 5.26 B as well as inspecting its technical indicators and probability of bankruptcy.
Fairly Valued
Today
Please note that Hikma Pharmaceuticals' price fluctuation is very steady at this time. Calculation of the real value of Hikma Pharmaceuticals PLC is based on 3 months time horizon. Increasing Hikma Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Hikma Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Hikma Pink Sheet. However, Hikma Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 49.81 | Real 49.71 | Hype 49.81 | Naive 47.84 |
The intrinsic value of Hikma Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Hikma Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Hikma Pharmaceuticals PLC helps investors to forecast how Hikma pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Hikma Pharmaceuticals more accurately as focusing exclusively on Hikma Pharmaceuticals' fundamentals will not take into account other important factors: Hikma Pharmaceuticals Total Value Analysis
Hikma Pharmaceuticals PLC is currently projected to have takeover price of 5.26 B with market capitalization of 4.72 B, debt of 651 M, and cash on hands of 393 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Hikma Pharmaceuticals fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
5.26 B | 4.72 B | 651 M | 393 M |
Hikma Pharmaceuticals Investor Information
The company has price-to-book (P/B) ratio of 1.89. Some equities with similar Price to Book (P/B) outperform the market in the long run. Hikma Pharmaceuticals PLC has Price/Earnings To Growth (PEG) ratio of 2.41. The entity last dividend was issued on the 18th of August 2022. Based on the key indicators related to Hikma Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Hikma Pharmaceuticals PLC is not in a good financial situation at this time. It has a very high probability of going through financial hardship in January.Hikma Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Hikma Pharmaceuticals has an asset utilization ratio of 58.39 percent. This suggests that the Company is making $0.58 for each dollar of assets. An increasing asset utilization means that Hikma Pharmaceuticals PLC is more efficient with each dollar of assets it utilizes for everyday operations.Hikma Pharmaceuticals Profitability Analysis
The company reported the revenue of 2.55 B. Net Income was 421 M with profit before overhead, payroll, taxes, and interest of 1.3 B.About Hikma Pharmaceuticals Valuation
Our relative valuation model uses a comparative analysis of Hikma Pharmaceuticals. We calculate exposure to Hikma Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Hikma Pharmaceuticals's related companies.Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company was founded in 1978 and is based in London, the United Kingdom. Hikma Pharmaceuticals operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 8700 people.
8 Steps to conduct Hikma Pharmaceuticals' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Hikma Pharmaceuticals' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Hikma Pharmaceuticals' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Hikma Pharmaceuticals' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Hikma Pharmaceuticals' revenue streams: Identify Hikma Pharmaceuticals' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Hikma Pharmaceuticals' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Hikma Pharmaceuticals' growth potential: Evaluate Hikma Pharmaceuticals' management, business model, and growth potential.
- Determine Hikma Pharmaceuticals' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Hikma Pharmaceuticals' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Hikma Pharmaceuticals Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 118 M | |
| Quarterly Earnings Growth Y O Y | -0.29 | |
| Forward Price Earnings | 9.1075 | |
| Retained Earnings | 2.2 B |
Additional Tools for Hikma Pink Sheet Analysis
When running Hikma Pharmaceuticals' price analysis, check to measure Hikma Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hikma Pharmaceuticals is operating at the current time. Most of Hikma Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Hikma Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hikma Pharmaceuticals' price. Additionally, you may evaluate how the addition of Hikma Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.